Pfizer and Flynn accused of overcharging NHS for anti-epilepsy drugs

Competition regulator the CMA alleges drugs firms abused dominant position with unfairly high prices

Pharmaceutical companies Pfizer and Flynn have been accused by the UK’s competition watchdog of illegally overcharging the NHS for vital anti-epilepsy drugs by abusing their dominance in the market to raise prices overnight.

The Competition and Markets Authority (CMA) has confirmed its 2016 finding that the pair exploited a loophole to charge unfairly high prices for phenytoin sodium capsules by debranding the drug, known as Epanutin, in 2012 so it would not face price regulation.

Continue reading...

from The Guardian https://ift.tt/3AduPXG